Dr Myles Suehiro completed his graduation from University of Colorado Boulder in 1965. He is a recipient of several fellowships and certification in Internal medicine including Fellowship in Anti-Aging Regenerative and Functional Medicine. He worked as an Assistant Professor at Charles R. Drew Postgraduate Medical School till 1986, after which he was appointed as the Director of I.C.U. at City View Hospital, Los Angeles and Medical Director at Cardio-Pulmonary Lab in 1990. He holds immensely vast experience in the field of medicine (more than 45 years) and is interested in the potential of treating rare disorders with the help of regenerative and functional medicine. At present he works as the Director of the Hawaii Institute for Health and Healing, LLC.
Dr Sergey Suchkov, MD, PhD. Professor in Immunology & Medicine. Director, Center for Personalized Medicine, Sechenov University and Chair,Dept for Translational Medicine, Moscow Engineering Physical Institute (MEPhI). Born on 11 Jan 1957, Astrakhan, Russia; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M.Sechenov First Moscow State Medical University, 1985; Doctor Degree, National Institute of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, Institute of Medical Enzymology; Head of the Lab of Immunology, Helmholtz Eye Research Institute in Moscow; Trainee, Laboratory of Immunology, NEI, Bethesda, MD, USA; Chair, Department for Clinical Immunology, Moscow Clinical Research Institute; Executive Secretary-in-Chief of the Editorial Board, Biomedical Science International journal. Honours: Secretary General, United Cultural Convention, Cambridge, UK. Memberships: New York Academy of Sciences, USA; ISPM, Tokyo, Japan; PMC, Washington, DC, USA; ACS, USA; AMEE, Dundee, UK; AHA, USA; EPMA, Brussels.
Dr. Yunyuan Li has completed his Ph.D. in 2005 from the University of Alberta, Canada. He is a currently a senior researcher at Burn and Wound Healing Research Laboratory at the University of British Columbia, Canada. His research interests were focused on the roles of hematopoietic cell-derived multi-potent stem cells in skin wound healing, hair follicle regeneration, and inflammation. Till now, Dr. Li has published over 40 articles in peer-reviewed journals.
Hematopoietic cell-derived multi-potent stem cells in skin wound healing
Dr. Wa Xian received her Bachelor’s degree in Biochemistry from Nankai University in China and Ph.D. degree in Molecular Genetics at the University of Texas Graduate School of Biomedical Sciences in Houston, focusing on master regulator genes of cell proliferation and lineage specification during early neural development. The support of a DOD breast cancer fellowship enabled Dr. Xian’s postdoctoral studies with Prof. Jeffrey Rosen at the Baylor College of Medicine. There she used a combination of ligand-induced dimerization strategies and a mammary epithelial 3D culture system to address the role of fibroblast receptor tyrosine kinase signaling in the evolution of breast cancer. In 2008, Dr. Xian moved to Harvard Medical School under the direction of Prof. Christopher Crum, Director of Women’s and Perinatal Pathology at the Brigham and Women’s Hospital to study the origin and evolution of ovarian cancer. Dr. Xian continues to work very closely with Prof. Crum on the origins and chemotherapy resistance problem in high-grade ovarian cancer. In 2009, Dr. Xian was appointed Principal Investigator at the Institute of Medical Biology of the Agency for Science, Technology, and Research in Singapore, where she jointly oversaw a highly interactive group of postdoctoral fellows, graduate students, and research assistants with Prof Frank McKeon of the Genome Institute of Singapore devoted to the cloning of stem cells of regenerative tissues and using advanced technologies to understand the genetics of their self-renewal, commitment, and differentiation. In 2013, Dr. Xian returned to the US and initiated multiple projects related to inflammatory diseases and cancer with colleagues at the University of Connecticut Health Center. In 2015, Dr. Xian received the Rising Stars Award from the Cancer Prevention & Research Institute of Texas (CPRIT) and was recruited to the Institute of Molecular Medicine at the University of Texas Health Science Center in Houston.
Biomarkers and Molecular imaging in gastrointestinal Cancer
Professor Ahmed Hashash has completed his PhD from Manchester University, UK. He is a fellow of the California Institute of Regenerative Medicine (CIRM) and New York University Medical School (MSSM), USA. Prof. Ahmed Hashash worked as a senior biomedical research scientist at Mount Sinai School of Medicine of New York University and Children’s Hospital Los Angeles. He was Assistant Professor and Principal Investigator of Stem Cell & Regenerative Medicine at Keck School of Medicine and Ostrow School of Dentistry of The University of Southern California, USA. In 2016, Prof. Hashash has joined The University of Edinburgh, Edinburgh Medical School-Zhejiang International Campus, (ZJU) as Tenure-Track Associate Professor and Senior Principal Investigator of Biomedicine, Stem Cell & Regenerative Medicine. He is also adjunct Professor at the School of Basic Medical Science and School of Medicine, Zhejiang University. Prof. Hashash has several breakthrough discoveries in genes/enzymes that control stem cell behavior and regenerative medicine. He has published more than 25 papers in reputed international journals and serving as an editorial board member of repute. Prof. El-Hashash acts as a discussion leader at the prestigious Gordon Research Seminar/Conference in USA, and a Peer Reviewer/ International Extramural Review for The Medical Research Council (MRC) grant applications, London, UK. He is invited to speak at several international conferences in USA, Spain, Greece, Egypt and China. He is the editor or author of several books on stem cell and regenerative medicine.
Stem Cell Therapy of Diseases & Cell and Developmental Biology
Bekir Cinar completed his Postdoctoral Fellowship, Boston Children’s Hospital, Harvard Medical School (HMS), Boston, MA (2002-2006) and Ph.D. from Department of Biochemistry and Molecular Genetics, School of Medicine University of Virginia, Charlottesville, VA (1995-2002), D.V.M., Veterinary Medical School, Ankara University, Ankara, Turkey (1987-1992). Currently he is working as Associate Professor, Department of Biological Sciences, Clark Atlanta University (CAU), Atlanta, GA 2015 to present. Presently, He is also member of the Center for Cancer Research and Therapeutic Development at CAU and a member of the NCI-designated Winship Comprehensive Cancer Center at Emory University. Prior to joining CAU, Dr. Cinar was Assistant Professor of Medicine-Hematology/Oncology and Biomedical Sciences at Cedars-Sinai Medical Center, where he was a member of Samuel Oschin Comprehensive Cancer Institute.
His research focus is on Signal Transduction, gene Expression, genomics, Proteomics, Bioinformatics, 3DCell Cultures
Mr. De la Parra is an entrepreneur focused on Information Technology, Education and Health. He is creative and results-driven and has 16+ years of Digital Strategy experience in architecture and implementation. Mr. De la Parra is the COO and Co-founding Partner at The Solomon Brokerage Firm. He currently leads as CEO at Mass Media Division & De la Parra Mobile Solutions, while also being the President of PetroM Renewable, VP of Operations & Strategy at PetroM Logistics, both divisions of PetroM Corp. Former COO & Co-founder at RegenerAge® Clinic & RegenerAge® Beauty & a member of the Board of Advisors. Former CEO & Founder at Astrum Salud Móvil and its Telemedicine service Astrum Móvil, former Digital Strategy Director & Co-founder at Dr. Jois®, BiorganicAging®, What Skin Needs™/WSN International Pty. Ltd. He also served as a member of the Board of Advisors and is former CMO at ReAnima Advanced Biosciences and former Digital Media Director at Bioquark, Inc. Within the academic and educational fields, Mr. De la Parra acted as the Executive Vice President: Executive Chairman of the WAMS Mobile Health Division, WAMS Chief Coordinating Officer, a member of the WAMS Executive Council (WAMS Executive Board), a member of the WAMS Education & Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty FWAMS, an Honorary Fellow of the Academy & is also a Senior Partner at WAMS, The World Academy of Medical Sciences. He is also an Advisory Board member, functioned as the Chief Operating Officer and is a Co-founding Partner at The Reprogramming Medicine Association. Mr. De la Parra is also a member of the National Introducing Brokers Association and a part of the National Biofuel Board, (Alliance Program), also being the founder and former Board of Directors member of Astrum Fundación, an Advisory Board member of the Lifeboat Foundation, an Advisory Board member of the Future Worlds Center - Cyprus Neuroscience & Technology Institute (Senior TV Program), a Federated member of the International Longevity Alliance, and volunteered as Digital Strategy adviser at the Major Mouse Testing Program. He is also a member of the Web Committee at the Life Extension Advocacy Foundation / Lifespan.io and has volunteered with SENS Research Foundation for the OncoSENS Program in Digital Strategy. Alejandro De la Parra Solomon is on Google+, Facebook, and on LinkedIn.
Neuroscience, Regenerative Medicine, Continued Medical Education, Information & Communications Technology, Biotechnology, Social Development
Dr. Jinsong Liu is a professor with tenure in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center since 2009. He received his medical degree from Shanghai Medical University 1983 and completed his Ph.D. from Case Western Reserve University in 1991, and post-doctoral training at the University of Michigan in 1993, pathology residency and surgical pathology fellowship training at New York University in 1999. Dr. Liu is an internationally recognized for his expertise in diagnostic pathology and research achievements in ovarian cancer. Dr. Liu has co-authored 213 original publications and has been an editorial member of several reputable journals.
His research interest has focused on the mechanisms of epithelial tumorigenesis, inflammation, and cancer stem cells.
A/Prof Yong Li obtained his PhD degree at University of New South Wales (UNSW) Sudney, Australia in 2000. He became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014; and an NHMRC Achievement Award (ranked No.1 in the industry fellow) in 2011. He was promoted to an Associate Professor in the Faculty of Medicine, UNSW since 2011, and a Principal Scientific Officer by the South Eastern Sydney Local Health District (SESLHD) since 2012. A/Prof Li has more than 100 career publications in cancer research area since 1999.
Associate Professor Li’s research is aimed at a): To investigate novel biomarkers from human body fluids and tissues, cancer cell lines and animal models for cancer diagnosis and monitoring cancer progression; b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance; c): To use targeted cancer therapy and combination therapy to control metastatic and therapeutic resistant cancers.
Dr. Mahajan completed his masters in General Surgery from Marathwada University, Maharashtra and went on to pursue Diploma in Urology at the University of Vienna, Austria. In a career changing move, after three decades of being a successful general and uro-surgeon, he started his brainchild-StemRx Bioscience Solutions Pvt. Ltd. in the year 2011. This was to focus on in-depth research in the field of Regenerative Medicine and Cell Based Therapy which he believes is the solution to address the limitations of conventional therapeutic modalities. To this effect, he underwent and continues to undergo intensive training in the United States. He has devised personalized treatment protocols in cell-based therapy for more than 75 health conditions. Dr. Mahajan is a Life member and Joint Secretary of The Stem Cell Society of India as well as Vice President of Anti-Aging Foundation, Delhi and Scientific National Advisor, Indian Stem Cell Study Group. He has been appointed as Hon. Associate Professor of Regenerative Medicine and Cell Based Therapy at Dr. R N Cooper Hospital, Mumbai and Faculty for MD Transfusion Medicine at KEM Hospital, Mumbai. Examiner for various fellowship courses with D.Y. Patil Institute, Kolhapur. Dr. Mahajan’s academic collaborations include being a Member of board of studies in ITM University, Raipur / MUHS, for PhD courses, M.Sc. and Fellowship Programs in stem cells and regenerative medicine. Among his international associations, a clinical trial in collaboration with the Ohio State University, USA on Cell Based Therapy for Avascular Necrosis is noteworthy, wherein Dr. Mahajan is a Principal Investigator. He is also a principal investigator in collaboration with Indiana University, Indianapolis under the guidance of Dr Chandan Sen to conduct the first human clinical trials using TNT technology in India. His recent international ventures include extension of StemRx facilities in Africa and collaboration with an organization in Japan to launch NK cell (cancer immunotherapy) technology for solid tumours in India. His company StemRx is also working on CAR-T cells technology in India. He has published an international patent for treatment of Avascular Necrosis using Regenerative Medicine approach and Indian patents for Avascular Necrosis, Ankylosing Spondylitis, Ischemic-tolerance Mesenchymal Stem Cell treatment/technology and isolation of dental pulp stem cells. He has 13 paper publications to his credit. Dr Mahajan has also been appointed by Government of India and Government of Maharashtra as consultant and panel doctor with the director general of shipping and labour department. Dr Mahajan is also associated with scholarly Journals for reviewing articles / research publication. Some of these are • Member, Editorial Board – ASMI • Member Editorial Board for reviewing scholarly articles, Gavin Publishers • Member Health Council – Head Hunt • Expert Reviewer – Journal of Scientific Research & Report • Expert Reviewer – British Journal of Medicine & Medical Research His drive to achieve tangible outcomes in research and therapy has earned him recognition and several awards in the field of healthcare—Paris Appreciation Award and National Awards for Excellence in Healthcare (Clinical Research category) for 2 consecutive years (2016 & 2017) to name a few. Recently he has also been featured in the Forbes Healthcare magazine for his pioneering work in the field of stem cell
Regenerative Medicine and Stem Cell
Ming Pei completed his PhD from Beijing University, China and Postdoc training from Harvard-MIT Division of Health Sciences and Technology, USA. Currently he is a tenured Professor and Director of Stem Cell and Tissue Engineering Laboratory in the Department of Orthopaedics, West Virginia University, USA. He has over 100 publications that have been cited over 3100 times, and his publication H-index is 32 and has been serving as an editorial board member of reputed Journals.
Stem cells, Tissue engineering, Biomaterials
Joo-Hyeon Lee was fascinated by stem cell research through Ph.D. studies under the supervision of Prof. Daesik Lim in KAIST, Korea. She then joined Prof. Carla Kim’s laboratory at Harvard Medical School where she became interested in the study of adult lung stem cells. She established her own research group at the Cambridge Stem Cell Institute in 2016 and focuses on understanding cellular behavior and regulatory networks of adult stem and niche cells. Joo-Hyeon is currently Faculty member at the Department of Physiology, Development, and Neuroscience, University of Cambridge and was recently awarded the Royal Society and Wellcome Trust Sir Henry Dale Fellowship and ERC starting grant.
Lee lab applies mouse genetics, ex vivo organoid co-cultures, live imaging, single-cell molecular analysis and mathematic modelling to define the identity and heterogeneity of diverse epithelial progenitor and mesenchymal populations, understand the key stem-mesenchymal interactions and the precise mechanisms that maintain tissue homeostasis and regeneration. Specifically, they are asking how the quiescent state is maintained and becomes activated, how cell fate is determined, and how niches develop and remodel in lung homeostasis, injury repair and early tumorigenesis.
Claire Acquaviva obtained her PhD at Montpellier University working on the proteolytic regulation of Fos transcription factors in Dr. Marc Piechaczyk’s laboratory at the Institute of Molecular Genetics of Montpellier (IGMM). She worked as a post-doc in Jonathon Pines’ laboratory at the Gurdon Institute in Cambridge (UK) on the regulation of the cell cycle by proteolysis. She returned to France in Marseille to work on the centrosome, primary cilia, cell cycle regulation and associated pathologies in Dr. Daniel Birnbaum’s laboratory at the CRCM.
Dr. Claire Acquaviva and Dr. Emilie Mamessier co-lead a group at the CRCM interested on Circulating Tumor Cells (CTCs) and their contribution to cancer metastases. Their main research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.
Dr. Murugan Ramalingam is Professor at the Centre for Biomaterials, Cellular & Molecular Theranostics, VIT University, India. He hss also Adjunct Professor at the Tohoku University, Japan and Professeur des Universite at the Faculté de Chirurgie Dentaire, Université de Strasbourg, France. He has worked at the WPI Advanced Institute for Materials Research, Japan, as an Assistant Professor. He has also worked at the National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH), under the U.S. National Academies Associateship program. He received his Ph.D. in Biomaterials from the CSIR-Central Leather Research Institute, University of Madras. He has also undergone training in Ethical and Policy issues on Stem Cells from Harvard University, USA, and in Operations Management from the University of Illinois-Chicago. His current research interests are focused on the development of multiphase biomedical materials, through conventional to nanotechnology to biomimetic approaches, microfabrication and bioprinting, cell patterning, stem cell differentiation, tissue engineering and drug delivery. He is the author of ~300 publications, including 20 textbooks relevant to nanotechnology, biomaterials, stem cells, tissue engineering and regenerative medicine. His current h-index is 40 with ~9400 citations. He has delivered several keynote/invited talks and has chaired/organized several international conferences related to Biomaterials, Bioprinting, Nanobiotechnology, Stem Cells and Tissue Engineering. He also serves as a board member of several international scientific and research committees in various public and private bodies and grant reviewer of various international funding agencies. He serves on the editorial boards of multiple biomaterials and tissue engineering-related journals, including the Editor-in-Chief of the Journal of Biomaterials and Tissue Engineering and the Journal of Bionanoscience. He is a recipient of several prestigious fellowships and awards, including CSIR Fellowship (India), Singapore Millennium Fellowship (SMF) (Singapore), NRC National Academies Fellowship (USA), Nationale Professeur des Universités (France), Fellow of Royal Society of Biology (UK), Fellow of Institute of Nanotechnology (UK) and Fellow of Royal Society of Chemistry (UK).
Stem Cell Research,Tissue Engineering
Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.
Dr. Tang and his colleagues have been studying cancer stem cells and cancer cell heterogeneity with a focus on prostate cancer. His career goals are to identify novel therapeutics and therapeutic combinations for personalized cancer treatment.
Magnus S Magnusson, Research Professor. Ph.D. in 1983, University of Copenhagen. Author of the T-pattern model and the corresponding detection algorithms in the T-pattern detection and Analysis software THEMETM (PatternVision.com). He has focused on real-time organisation of behavior, co-directed DNA analysis, published numerous papers and given invited talks and keynotes at universities in Europe, USA and Japan and at international conferences in ethology, psychology, neuroscience, mathematical sciences, science of religion, proteomics and mass spectrometry. Deputy Director 1983-1988 in the Museum of Mankind, National Museum of Natural History, Paris. Repeatedly invited Professor in psychology and ethology (the biology of behavior) at the University of Paris, V, VIII and XIII. Since 1991, Founder and Director of the Human Behavior Laboratory (hbl.hi.is), University of Iceland. He works in collaboration between now 32 universities on Methodology for the Analysis of Social Interaction (MASI) initiated in 1995 at the Sorbonne, Paris based on “Magnusson’s analytical model
Molecular Biology, Proteomics, Boinformatics, Mass Spectrometry, Genetics, Human Computer Interaction,
Dr. Heggeness completed his PhD at UC San Diego in membrane biology, and a postdoc at Rockefeller University in Virology. He received his MD from the University of Miami. After a residency in Orthopaedic Surgery, he completing a fellowship in Spine Surgery at the University of Toronto. He then joined the faculty at Baylor College of Medicine where he became Chairman of Orthopaedic Surgery in 2004. He moved take the Orthopaedic Surgery Chair at University of Kansas in Wichita in 2013. He has 84 publications and 4 issued patents.
His interest has centered on intraosseous nerves, and recently, nerve derived stem cells.
Dennis M. Lox M.D., Graduated from the University of Arizona Phi Beta Kappa, and Phi Kappa Phi. His medical education was from Texas Tech University and his Residency in Physical Medicine and Rehabilitation at the University of Texas Health Sciences Center at San Antonio. Dr. Lox choose a path following Sports and Regenerative Medicine. Dr. Lox has edited two medical textbooks, eight medical textbook chapters, and authored numerous scientific articles and abstracts. Dr. Lox is a highly sought after guest lecturer at both National and International Medical Symposiums on various topics in the Regenerative Medicine, Stem Cell Science, and Tissue Engineering fields. Dr. Dennis Lox maintains an active clinical practice in Beverly Hills, California, and the Tampa Bay, Florida area.
Sports medicine, Stem cells and Regenerative medicine
Dr. Yusuke Yamamoto completed his Ph.D. in Molecular Physiology from Waseda University, Japan in 2008. He further pursued his postdoctoral studies under the supervision of Prof. Frank McKeon and A/Prof. Wa Xian at Genome Institute of Singapore. Presently, he is working as a Senior Staff Scientist at National Cancer Center Research Institute, Japan. He has been interested in how adult stem cells maintain their stemness throughout the lifespan as well as identifying cell-of-origin in esophageal adenocarcinomas and high grade serous ovarian carcinoma, which are the most aggressive type of cancers with poor prognosis. With his outstanding research work, he has published more than 40 papers in peer-reviewed journals, including Nature and Cell and holds one US patent on ‘Nanobio device of imitative anatomy structure’ in 2010 while another one, ‘Novel Diagnosis and Therapeutic Targets for Cervical Cancer’ is in the pipeline. He has presented his various research work in 15 national and international conferences and is a member of The Molecular Biology Society of Japan, Japanese Cancer Association and The Japanese Biochemical Society.